Human antibodies to bacterial polyaaccharides consist primarily of IgG and are largely restricted to the IgG2 subclass. We examined the ontogeny of the IgG subclass response to pneumococcal ...

Herd immunity generated by the introduction of the 13-valent pneumococcal conjugate vaccine in the United States — first in 2010 for children, then in 2012 for immunocompromised adults, in series with ...

Pneumococcal vaccines, including pneumococcal polysaccharide vaccine (PPV) and pneumococcal conjugated vaccine (PCV), are crucial in preventing invasive pneumococcal diseases. We analyzed the ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive (pneumococcal polysaccharide conjugate vaccine [21-valent]) intended to ...

To improve diagnostic options for pneumococcal pneumonia, an ELISA system was developed that can detect ⩽6 ng/ml capsular polysaccharide in serum. The test was limited to 39 serotypes causing >95% of ...

Pfizer Receives FDA Approval to Extend Use of Prevnar 13® for Prevention of Pneumococcal Pneumonia and Invasive Disease in Adults 50 Years and Older First pneumococcal conjugate vaccine for adults 50+ ...

"We observed wide variation across pneumococcal conjugate vaccine (PCV) products in serotype coverage and potentially preventable burdens. Variation in both invasive and mucosal disease coverage and ...

Pneumococcal polysaccharide vaccination of healthcare workers during an influenza pandemic is cost-effective from a societal perspective but not from a hospital perspective without external subsidy.